Thymidine Auxotrophic *Staphylococcus aureus* Small-Colony Variant Endocarditis and Left Ventricular Assist Device Infection

Awele Maduka-Ezeh,a Maria Teresa Seville,b Shimon Kusne,b Holenarasipur R. Vikram,b Janis E. Blair,b Kerryl Greenwood-Quaintance,c Francisco Arabia,a and Robin Patelec

Division of Infectious Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USAa; Division of Infectious Diseases, Department of Internal Medicine, Mayo Clinic, Phoenix, Arizona, USAa; Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USAa, and Division of Cardiovascular and Thoracic Surgery, Mayo Clinic, Phoenix, Arizona, USAa

We describe a thymidine-dependent small-colony variant of *Staphylococcus aureus* associated with left ventricular assist device infection and prosthetic valve and pacemaker endocarditis.

CASE REPORT

The patient was a 34-year-old woman who 3 years prior had suffered an anterior wall myocardial infarction resulting in ischemic cardiomyopathy, which necessitated placement of a pacemaker biventricular defibrillator. Subsequently, there was progressive deterioration of cardiac function. A left ventricular assist device (LVAD) was placed as a bridge to heart transplantation. During the same surgery, her native tricuspid valve was replaced with a pericardial tissue valve on account of tricuspid regurgitation. One month after surgery, she developed fever and was placed with a pericardial tissue valve on account of tricuspid regurgitation. During the same surgery, her native tricuspid valve was replaced with a porcine tissue valve.

We describe a thymidine-dependent small-colony variant of *Staphylococcus aureus* associated with left ventricular assist device infection and prosthetic valve and pacemaker endocarditis.
bial pressure (and thus the need for expression of the SCV phenotype) is removed (20). It has been suggested that the ability to switch between SCV and normal morphology colonies may be associated with intermittent reoccurrence of active infection (as normal morphology colonies) with periods of quiescence in between (when isolates exist as SCV forms) (21). For each passage, following 24 h of incubation at 37°C, a subculture was made on a fresh SBA plate. Passaging was done simultaneously in air and 5% CO₂. Plates grown in air were compared to those grown in 5% CO₂, and any differences noted. Each step was done in duplicate. The experiment was repeated on two separate occasions. With serial passage on SBA, either in air or CO₂, colonies reverted to normal-diameter (>1-mm) colonies by the second or third passage. Further passaging of these normal colonies resulted in reversion back to the SCV phenotype. Up to five more passages were subsequently done with no reappearance of the normal phenotype. To the best of our knowledge, this fluctuating phenotype has not been previously described.

Hemin, thymidine, and menadione auxotrophy were tested by the disc and agar methods. For the disc method, commercially available 10% hemin discs (Sigma-Aldrich, Saint Louis, MO) or discs impregnated with thymidine (100 μg/ml) or menadione (25 μg/ml) were placed on Mueller-Hinton agar (MHA) plates inoculated with a 0.5 McFarland standard of the isolate. The isolate was considered auxotrophic if it showed normal colonies or increased growth surrounding the impregnated disc compared to the periphery following 24 h of incubation in air at 37°C (5, 17). For the agar method, following growth overnight on SBA, 3 to 4 similar colonies were inoculated onto MHA with and without supplementation with 125 μg/ml thymidine, 25 μg/ml menadione, or 10 μg/ml hemin. Auxotrophy was considered present if the isolate grew as normal-sized colonies on supplemented versus nonsupplemented MHA. Each step was done in duplicate, and the experiment was repeated on two separate days. S. aureus menD and hemB knockout mutants provided by C. Von Eiff (Institute of Medical Microbiology, University Hospital Münster, Germany) were used as menadione and hemin controls (3, 27). Auxotrophy testing for CO₂ was done by comparing growth at 37°C in air with that in 5% CO₂. The isolate was thymidine dependent, growing only on MHA supplemented with 125 μg/ml of thymidine and around discs impregnated with 100 μg/ml of thymidine, but not on MHA alone. Hemin, menadione, and CO₂ auxotrophy were negative.

**mecA** PCR, done with the primers mec449F, 5'-AAA CTA CGG TAA CAT TGA TCG CAA C-3', and mec761R, 5'-CTT GTA CGG TAA CAT TGA TCG CAA C-3' (18), was positive. Antimicrobial susceptibility was tested by Etest (bioMérieux, Marcy l'Etoile, France) by following the manufacturer’s instructions (except that 5% defibrinated sheep blood was added to the medium, as previously described (5, 6)) for all tested antimicrobics except gentamicin, amikacin, tobramycin, and kanamycin, which were tested by agar dilution following Clinical and Laboratory Standards Institutes guidelines (10) (except that 5% defibrinated sheep blood was added to the media, as previously described (5, 6)).

All testing was simultaneously performed on control strain S. aureus ATCC 29213 and was within the quality control range specified by Clinical and Laboratory Standards Institutes guidelines (11). In addition to reading susceptibilities at 20 h (24 h for oxacillin and vancomycin), susceptibilities were read at 48 h. The isolate was resistant to tobramycin, amikacin, and kanamycin (MIC, >16, >64, and >64 μg/ml, respectively) but susceptible to gentamicin (MIC, ≤0.5 μg/ml). The isolate was resistant to oxacillin and cefoxitin (MIC, >256 and >256 μg/ml, respectively) and resistant to TMP-SMX (MIC, >32/608 μg/ml). Similar results (≤1 dilution difference) were obtained when MICs were rered at 48 h. The isolate was rifampin resistant (MIC, >32 μg/ml) but susceptible to vancomycin, minocycline, and linezolid (MIC, 1, 0.032, and 0.025 μg/ml, respectively).

Biofilm and planktonic growth rates were measured as follows: a culture of the isolate in Trypticase soy broth (TSB) was adjusted to match the turbidity of a 1.0 McFarland standard and then diluted 1:50 in TSB. Aliquots of 200 μl were placed into four wells of seven 96-well microtiter plates corresponding to incubation times of 6, 12, 24, 48, 72, 96, and 120 h. Planktonic growth at each of the

![FIG 1 Duration of antimicrobials administered over time (through device explantation, day 482). Arrowheads, S. aureus bacteremia episodes; horizontal gray bars, number of days each antibiotic was given; Quin/Dal, quinupristin-dalfopristin; TMP/SMX, trimethoprim-sulfamethoxazole.](http://jcm.asm.org/Downloaded from July 5, 2017 by guest)
time points was measured by an optical density at 600 nm (OD\textsubscript{600}) using a Multiskan microtiter plate reader (Thermo Electron, Waltham, MA). Culture medium was discarded, and wells were washed twice by submerging plates in deionized water to remove nonadherent cells. Plates were air dried overnight. Biofilms were then stained with 0.1% safranin for 1 min, rinsed under running tap water to remove excess stain, and air dried. Stained biofilms were resuspended in 200 μl 30% glacial acetic acid, and the OD\textsubscript{492} was measured. Wells containing unincubated medium served as negative controls. *Staphylococcus epidermidis* ATCC 35984 (RP62A) was used as a positive control. The biofilm index (biofilm OD\textsubscript{492}/planktonic OD\textsubscript{600}), which measures biofilm formation corrected for rate of cell growth, thus allowing comparison between slower and faster growing isolates, was calculated (12, 14, 19). The experiment was repeated at three different times. IDRL-8699 was a poor biofilm former compared to the positive-control strain, showing a biofilm index that was less than the negative control.

Following replacement of her infected prosthetic tricuspid valve and LVAD, the patient has done well on chronic antimicrobial suppression without evidence of recurrent infection with *S. aureus* during 18 months of follow-up.

Cardiac devices, including pacemakers and implantable cardioverter defibrillators, as well as LVADs, are increasingly used (8, 16, 22). Accompanying increased use of these devices has been an increase in both the total number and in the rates of infections of these devices (8). Cardiac device and LVAD infections result in significant morbidity and reduced patient survival (8, 16).

SCVs are a subpopulation of bacteria that have been associated with persistent and difficult-to-treat infections of both native tissue and prosthetic material. Best described for *S. aureus*, the purported mechanisms behind their persistence include antimicrobial resistance (4), enhanced biofilm formation (24, 25), and the ability to exist for prolonged periods in the intracellular milieu (2, 26, 28). Conceivably, purulent secretions containing deteriorating cells, the DNA of which can be degraded by *S. aureus* DNase, present around the LVAD could result in a supply of thymidine, supporting growth of thymidine-dependent *S. aureus* (7, 15, 28). Thymidine auxotrophic *S. aureus* SCVs have been frequently isolated from the lungs of cystic fibrosis patients and (less frequently) from patients with chronic soft tissue infection, tmypanitis, bronchitis, peritonitis, and bacteremia (7) but have not been previously reported in association with endocarditis, pacemaker infection, or LVAD infection.

Thymidine auxotrophs are thought to arise due to antibiotic pressure after prolonged exposure to TMP-SMX (6, 7). This has been best described in isolates from the airways of cystic fibrosis patients on chronic TMP-SMX therapy (15, 17), but long-term TMP-SMX has also been associated with thymidine auxotrophy in *S. aureus* isolates from patients without cystic fibrosis (7). Thymidine auxotrophic SCVs have been shown to harbor mutations within the thymidylate synthase-encoding *thyA* gene (5, 7, 9). Whether or not *thyA* is mutated in the IDRL-8699 was not determined.

It is likely that most clinical laboratories would not be able to perform antimicrobial susceptibility testing on thymidine-dependent *S. aureus*. Thymidine auxotrophs are generally considered resistant to TMP-SMX due to utilization of extracellular deoxythymidine monophosphate, bypassing the pathway targeted by TMP-SMX (7, 15, 28). The ideal approach to assessing the antimicrobial susceptibility of thymidine-dependent *S. aureus* SCVs is unclear. We assessed susceptibility using MHA supplemented with 5% defibrinated sheep blood, as described by Besier et al. (5, 6). The addition of defibrinated sheep blood is not recommended by the Clinical and Laboratory Standards Institutes or the manufacturer of Etest strips, as it may supply constituents that bypass the effects of TMP-SMX, potentially causing TMP-SMX-susceptible strains to appear resistant to TMP-SMX (13). Nevertheless, it is otherwise impossible to assess the TMP-SMX susceptibility of such isolates, and the control strain, *S. aureus* ATCC 29213, tested TMP-SMX susceptible in our experiments, supporting the use of this method.

To complicate matters, reversion of thymidine-dependent *S. aureus* SCVs has been previously described in association with loss of both thymidine auxotrophy and TMP-SMX resistance (7). “False” TMP-SMX susceptibility due to reversion of *thyA* mutations in the laboratory or the copresence of isolates with and without such mutations and the inability to perform routine susceptibility testing on thymidine-dependent isolates when using automated instruments or following Clinical and Laboratory Standards Institutes guidelines along with a false assumption that *S. aureus* is generally TMP-SMX susceptible could potentially drive inappropriate TMP-SMX therapy of thymidine-dependent *S. aureus*. At our institution, more than 97% of *S. aureus* isolates (that can be tested for TMP-SMX susceptibility following Clinical and Laboratory Standards Institutes guidelines) are reported as being susceptible to TMP-SMX. Indeed, in the case described herein, TMP-SMX was initially selected (along with minocycline) for antimicrobial suppression.

Thymidine auxotrophs of *S. aureus* have been shown to be hypermutable and therefore might be more likely to acquire mutational antimicrobial resistance than normal colony phenotypes (6). Although we did not address this in our study, it is possible that hypermutability was present in our patient’s *S. aureus*, influencing the emergence of rifampin resistance and daptomycin nonsusceptibility.

Enhanced biofilm formation by laboratory-selected strains of menadione auxotrophic *S. aureus* has been well described (24, 25). Interestingly, despite the persistent infection produced by IDRL-8699, it did not form substantial biofilm in vitro. One possible explanation is that there might be conditions present in vivo, but not in the in vitro environment tested, which support enhanced biofilm formation. This could also be a function of the specific assay used to assess biofilm formation. Another possibility is that enhanced biofilm formation is a characteristic of menadione but not thymidine auxotrophic SCVs. Indeed, poor (but extant) biofilm formation could account for clinically quiescent but persistent infections associated with SCVs.

In summary, the case is presented here of a thymidine-dependent SCV associated with LVAD infection and prosthetic valve and pacemaker endocarditis in a 34-year-old woman. With passage on antimicrobial free medium, the isolate exhibited a fluctuating phenotype, going from small- to normal-sized-colony phenotypes and back again to the small-colony phenotype.

(This work was presented in part at the 11th International Symposium on Modern Concepts in Endocarditis and Cardiovascular Infections, Cairns, Australia, 24 to 26 July 2011.)
ACKNOWLEDGMENTS
We thank the outstanding staff of the Mayo Clinic Rochester and Arizona Bacteriology laboratories, especially Rebecca A. Stewart, Peggy C. Kohner, Scott A. Cunningham, and Sherry M. Ihde, for their assistance with this case.

REFERENCES